ProMIS Neurosciences Announces Board and Executive Changes
Ticker: PMN · Form: 8-K · Filed: Sep 30, 2025
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
ProMIS Neurosciences shakes up its board and exec pay structure.
AI Summary
ProMIS Neurosciences Inc. announced on September 26, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory plans for key personnel.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial stability.
Key Players & Entities
- ProMIS Neurosciences Inc. (company) — Registrant
- September 26, 2025 (date) — Date of earliest event reported
- Toronto, Ontario, Canada (location) — Business and mail address
FAQ
What specific roles have seen departures or appointments?
The filing indicates the departure of certain officers and the election of new directors, but does not specify the exact roles affected in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 26, 2025.
What is the primary business of ProMIS Neurosciences Inc.?
ProMIS Neurosciences Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is ProMIS Neurosciences Inc. headquartered?
The company's business and mail address is Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada.
What sections of the Securities Exchange Act of 1934 are relevant to this filing?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-30 16:15:13
Key Financial Figures
- $500,000 — t provides for an annual base salary of $500,000 CAD and an annual discretionary bonus w
Filing Documents
- pmn-20250926x8k.htm (8-K) — 36KB
- pmn-20250926xex10d1.htm (EX-10.1) — 64KB
- 0001104659-25-095032.txt ( ) — 238KB
- pmn-20250926.xsd (EX-101.SCH) — 3KB
- pmn-20250926_def.xml (EX-101.DEF) — 3KB
- pmn-20250926_lab.xml (EX-101.LAB) — 18KB
- pmn-20250926_pre.xml (EX-101.PRE) — 12KB
- pmn-20250926x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amended and Restated Employment Agreement with Neil Cashman 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: September 30, 2025 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer